SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia-Reference-Cited by-同舟云学术

SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia

Published:2014-07-18 Issue:2 Volume:167 Page:233-237
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Advani Anjali S.¹,McDonough Shannon²,Copelan Edward³,Willman Cheryl⁴,Mulford Deborah A.⁵,List Alan F.⁶,Sekeres Mikkael A.¹,Othus Megan²,Appelbaum Frederick R.⁷

Affiliation:

1. Department of Hematologic Oncology and Blood Disorders; The Cleveland Clinic; Taussig Cancer Institute; Cleveland OH USA

2. SWOG Statistical Center; Seattle WA USA

3. Levine Cancer Institute; Carolinas Healthcare System; Charlotte NC USA

4. University of New Mexico Cancer Center; Albuquerque NM USA

5. University of Rochester Medical Center; Rochester NY USA

6. H. Lee Moffitt Cancer Center and Research Institute; Tampa FL USA

7. Fred Hutchinson Cancer Research Center; Seattle WA USA

Funder

National Cancer Institute

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13035/fullpdf

Reference20 articles.

1. Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukaemia cells;Banker;Blood,2004

2. European development of clofarabine as treatment for older patients with acute myeloid leukaemia considered unsuitable for intensive chemotherapy;Burnett;Journal of Clinical Oncology,2010

3. Revised recommendations of the Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukaemia;Cheson;Journal of Clinical Oncology,2003

4. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukaemia;Estey;Blood,1996

5. Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukaemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts;Estey;Blood,2001

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges;Current Obesity Reports;2023-12-30

2. CCR9 overexpression promotes T-ALL progression by enhancing cholesterol biosynthesis;Frontiers in Pharmacology;2023-09-06

3. The role of cholesterol metabolism in tumor therapy, from bench to bed;Frontiers in Pharmacology;2023-04-06

4. Metabolism in acute myeloid leukemia: mechanistic insights and therapeutic targets;Blood;2023-03-09

5. RHOA Therapeutic Targeting in Hematological Cancers;Cells;2023-01-28